Olanzapine in pediatric chemotherapy induced nausea and vomiting in

Assessing the effectiveness of olanzapine in treating nausea and vomiting caused by chemotherapy in children.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120415009475N14

Enrollment

Registered

2023-10-11

Start date

2023-11-22

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced nausea and vomiting.

Interventions

Intervention 1: Intervention group: Olanzapine dosing 0.1 milligrams per kilogram once daily at bedtime starting with chemotherapy for 3 days. Intervention 2: Control group: Placebo with the same pack

Eligibility

Sex/Gender

All

Age

1 Years to 15 Years

Inclusion criteria

Inclusion criteria: Pediatric patients undergoing chemotherapy with medications inducing moderate to severe nausea

Exclusion criteria

Exclusion criteria: Heart failure or heart disease associated with the risk of Arrhythmia. Epilepsy Kidney failure Liver failure Mechanical ventilation

Design outcomes

Primary

Measure	Time frame
Occurrence of nausea and vomiting. Timepoint: Daily for 7 days. Method of measurement: Questionare.	—

Secondary

Measure	Time frame
Oral intake tolerance. Timepoint: Daily for 7 days. Method of measurement: Questionare.;Weight loss. Timepoint: Daily for 7 days. Method of measurement: Weighing.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Alibabaee

Shahid Beheshti University of Medical Sciences

ne_gar_babaee@yahoo.com0098 21 021 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026